Day 1 | Day 2
Monday, August 24, 2009
12:00pm Main Conference Registration
1:30 Opening Chairperson’s Remarks
Fubao Wang, Ph.D., Senior Research Fellow, Vaccine and Biologics Research, Merck & Co., Inc.
Opening Keynote PRESENTATION
1:40 Biopharmaceutical Expression Systems: Opportunities for Innovators, CMOs and Product Developers
Eric Langer, Ph.D., President, BioPlan Associates Inc.
In this presentation, we explore the rapid shifts in expression system technology developments today. We identify emerging platform technologies and their impact on yield and quality, as well as royalty issues associated with new expression systems.
|
2:20 Expression of Recombinant Haemophilus influenzae IgA1 Protease
Shinong Long, Ph.D., Scientist, Research and Development, BioMarin Pharmaceuticals, Inc.
The IgA1 protease may have the potential to cleave IgA complex in the kidney and therefore could have potential as a therapeutic agent for IgA nephropathy (IgAN), a disease characterized by deposition of the IgA antibody in the glomerulus. We have screened for the expression of recombinant IgA1 protease by using different expression plasmids, different IgA protease constructs, and different E. coli strains under different conditions. This is the first report of expression of recombinant soluble and active forms of H. influenzae IgA protease in E. coli.
2:55 Large-Scale Production of Functional Proteins in Insect Larvaee
Elena Kovaleva, Ph.D., Head, R&D, Protein Expression and Recovery Labs, Chesapeake PERL, Inc.
Chesapeake PERL, Inc. has developed a unique technology for the automated mass rearing and oral infection of millions of larvae with recombinant baculovirus. Rapid scaling allows production of high-quality proteins required for human pharmaceuticals in multi-gram quantities. Using whole larvae as “mini bioreactors” along with visually detected marker, co-infection, host-adapted chaperons and other techniques, we can overcome many drawbacks associated with large-scale protein production in cell culture systems. Among the proteins expressed are VLP structurally identical to native; viral proteins for vaccine development, shown to have in vivo activity in primates; human enzymes and hormones for medical and defense threat fields.
3:25 Networking Refreshment Break with Exhibit and Poster Viewing
4:05 Moderated Small-Group Breakout Discussions
Join with your colleagues to discuss the crucial issues associated with culturing mammalian cells and expressing protein using specialized host systems. Small-group discussions are a great way to network, exchange information, and develop collaborations. Each table topic is facilitated by an expert in the field, and discussions can be lively and spirited.
Solving Protein Expression Problems using High Throughput Screens
Host: Geoffrey Waldo, Ph.D., Los Alamos National Laboratory
- Protein folding
- Complex formation
- Solubility using novel reporter tags
How Budgets Impact Your Science
Host: Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
- the adoption of new expression systems
- downstream technologies
- disposables today
Protein Expression for Crystallization: Solving Problems in the Process
Host: Joseph Ng, Ph.D., Associate Professor, University of Alabama, Huntsville
Making Inclusion Bodies Work for You
Peter Sondermann, Ph.D., CSO, SuppreMol GmbH
- Suitable targets for IB based production
- Expression construct design
- Refolding strategies
- Design of the whole production process
5:15 Roundtable Report Out – Each topic leader will present a brief report of the group’s discussion to the meeting delegates.
5:30 Reception in the Exhibit Hall (Sponsorship Available)
6:30 End of Day
For more information, please contact:
Elizabeth Lamb, Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-493-7874
E-mail:
elamb@healthtech.comFor exhibit and sponsorship information, please contact:
Suzanne Carroll, Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972- 5452
E-mail: scarroll@healthtech.com